Pharmacovigilance And Drug Safety Software Market Report 2026

Pharmacovigilance And Drug Safety Software Market Overview

• Pharmacovigilance And Drug Safety Software market size has reached to $2.53 billion in 2025 • Expected to grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 12.6% • Growth Driver: Increasing Adoption Of Personalized Medicine Drives Growth In The Pharmacovigilance And Drug Safety Software Market • Market Trend: Cloud-Based Data Lake Platforms Revolutionizing Pharmacovigilance And Drug Safety Software Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the pharmacovigilance and drug safety software market include: • Fully Integrated Software (Segmentation By Software Type) → Expected gain of $0.68 Billion • Adverse Event Reporting Software (Segmentation By Software Type) → Expected gain of $0.61 Billion • Issue Tracking Software (Segmentation By Software Type) → Expected gain of $0.41 Billion

What Is Covered Under Pharmacovigilance And Drug Safety Software Market?

Pharmacovigilance and drug safety software refers to a suite of digital tools designed to monitor, analyze, and report adverse drug reactions (ADRs) and other safety-related information associated with pharmaceuticals and medical products. This software plays a critical role in ensuring patient safety and regulatory compliance throughout the lifecycle of a drug, from development to post-marketing surveillance. The main software types of pharmacovigilance and drug safety software are adverse event reporting software, drug safety audit software, issue tracking software, and fully integrated software. Adverse event reporting software is designed to track, document, and manage adverse events related to pharmaceutical products or medical devices. The delivery modes are on-premise and cloud-based and used by various end users, such as pharmaceutical and biotechnology companies, contract research organizations, business process outsourcing firms, and others.

What Is The Pharmacovigilance And Drug Safety Software Market Growth Forecast?

The pharmacovigilance and drug safety software market size is expected to see rapid growth in the next few years. It will grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to expansion of ai-driven signal detection, growth in biologics and specialty drugs, rising regulatory scrutiny, increasing outsourcing of pharmacovigilance services, demand for real-time safety analytics. Major trends in the forecast period include growing adoption of cloud-based pharmacovigilance platforms, increasing focus on real-world evidence monitoring, rising automation in adverse event reporting, expansion of integrated drug safety systems, higher demand for regulatory compliance solutions.

What Is The Driver Of The Pharmacovigilance And Drug Safety Software Market?

The growing demand for personalized medicine is expected to propel the growth of the pharmacovigilance and drug safety software market going forward. Personalized medicine, also known as precision medicine, is a healthcare approach that tailors treatment decisions to an individual’s genetic, biological, and lifestyle characteristics. The demand for personalized medicine is rising due to improved treatment outcomes, enhanced prevention and early detection strategies, and greater cost-effectiveness. The pharmacovigilance and drug safety software market supports personalized medicine by integrating pharmacogenetics, real-time data analytics, and post-marketing surveillance to optimize patient safety, monitor individualized treatments, and strengthen risk-management practices. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to 6 approvals in 2022. Therefore, the growing demand for personalized medicine is driving the growth of the pharmacovigilance and drug safety software industry.

How Will The Drivers Impact Growth In The Global Pharmacovigilance And Drug Safety Software Market?

• Rising Volume And Complexity Of Drug Development Pipelines (High) – During the forecast period, the rising volume and complexity of drug development pipelines is expected to become a key growth driver for the pharmacovigilance and drug safety software market by 2030. The increasing number of clinical trials, coupled with the growing diversity of therapeutic areas including biologics, gene therapies, and personalized medicines, is generating large volumes of safety data that require efficient processing and analysis. This complexity is pushing organizations to adopt advanced software solutions that can manage multi-source data, ensure traceability, and support end-to-end safety workflows. Additionally, the need to monitor drug safety across global trial sites and post-marketing environments is further accelerating adoption. • Increasing Incidence And Awareness Of Adverse Drug Reactions (ADRs) (High) – During the forecast period, the increasing incidence and awareness of adverse drug reactions (ADRs) is expected to emerge as a major factor driving the expansion of the pharmacovigilance and drug safety software market by 2030. Growing public health awareness, improved reporting mechanisms, and heightened focus on patient safety are leading to a surge in ADR reporting from healthcare professionals and patients. Regulatory authorities are also emphasizing proactive risk detection and continuous monitoring, prompting companies to enhance their pharmacovigilance capabilities. This environment is encouraging the deployment of software solutions that support faster case identification, validation, and reporting. • Expansion Of Outsourcing And CRO-Based Pharmacovigilance Operations (Medium) – During the forecast period, the expansion of outsourcing and CRO-based pharmacovigilance operations is expected to act as a key growth catalyst for the pharmacovigilance and drug safety software market by 2030. Pharmaceutical companies are increasingly partnering with contract research organizations and specialized service providers to manage growing safety workloads while optimizing operational efficiency. This shift is driving demand for scalable, standardized, and interoperable software platforms that can support distributed teams and multi-client environments. Additionally, outsourcing models require robust tracking, reporting, and compliance capabilities, further boosting software adoption. As outsourcing continues to expand globally, the need for integrated pharmacovigilance systems is expected to rise.

How Will The Restraints Impact Growth In The Global Pharmacovigilance And Drug Safety Software Market?

• High Operational Costs And Resource Intensity (High) – During the forecast period, high operational costs and resource intensity are restricting the growth of the pharmacovigilance and drug safety software market. Significant investment required for software deployment, data management, compliance processes, and continuous monitoring is increasing financial burden on pharmaceutical companies • Data Quality, Standardization, And Integration Challenges (High) – During the forecast period, data quality, standardization, and integration challenges are restricting the growth of the pharmacovigilance and drug safety software market. Inconsistent data formats, lack of standardized reporting systems, and difficulties in integrating multiple data sources are creating inefficiencies and slowing adoption • Shortage Of Skilled Pharmacovigilance Professionals (Medium) – During the forecast period, shortage of skilled pharmacovigilance professionals is restricting the growth of the pharmacovigilance and drug safety software market. Limited availability of experts in drug safety monitoring, regulatory compliance, and data analysis is hindering effective utilization of these platforms

Key Players In The Global Pharmacovigilance And Drug Safety Software Market

Major companies operating in the pharmacovigilance and drug safety software market are IQVIA, Oracle Corporation, ArisGlobal, RXLogix, Anju Software Inc., EXTEDO GmbH, Sarjen Systems Pvt Ltd, Ennov Group, AB Cube, Clinevo Technologies, Accenture plc, International Business Machines Corporation, Capgemini SE, Cognizant Technology Solutions, Wipro Limited, Genpact, Indegene Limited, PharmaLex, Deloitte Touche Tohmatsu Limited, Parexel

Global Pharmacovigilance And Drug Safety Software Market Trends and Insights

Major companies operating in the pharmacovigilance and drug safety software market are focusing on developing innovative technologies such as cloud-based data lake platforms to strengthen adverse event monitoring, improve regulatory compliance, and enhance overall patient safety across clinical trials and post-market surveillance. A cloud-based data lake platform refers to a scalable centralized system capable of storing and analyzing large volumes of structured and unstructured safety data in real time, enabling advanced analytics, AI/ML modeling, and streamlined case processing within pharmacovigilance workflows. For instance, in December 2023, Thermo Fisher Scientific Inc., a US-based biotechnology company, launched CorEvidence, a proprietary cloud-based data lake platform designed to optimize pharmacovigilance processes by improving safety data management and case processing efficiency, particularly supporting post-authorization safety studies within clinical research registries.

What Are Latest Mergers And Acquisitions In The Pharmacovigilance And Drug Safety Software Market?

In April 2024, Qinecsa, a UK-based company, acquired Insife ApS for an undisclosed amount. This acquisition strengthens Qinecsa’s end-to-end pharmacovigilance technology capabilities by integrating Insife’s advanced safety-software solutions into its digital PV ecosystem. It further enhances Qinecsa’s position in the global pharmacovigilance market by expanding its technology portfolio and supporting its strategy to become a leading provider of digital PV solutions. Insife ApS is a Denmark-based provider of pharmacovigilance software.

What Defines the Pharmacovigilance And Drug Safety Software Market?

The pharmacovigilance and drug safety software market includes revenues earned by entities by signal detection and management tools, risk assessment, and management software. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pharmacovigilance And Drug Safety Software Market Report 2026?

The pharmacovigilance and drug safety software market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacovigilance and drug safety software industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.